← My Government dashboard

Government Watch

Dossier Executive proposed rule 27-jul-2026 Comment closes · 10-sep-2026
Draft regulation published for public comment — not yet in force.

Reducing Barriers to Medical Use Licensing

Key claim: The NRC proposes to amend its medical-use licensing regulations to cut overly prescriptive requirements, ease training and experience burdens for authorized users, and make licensing of emerging medical technologies that use byproduct material more efficient and predictable.

Abstract

(Proposed Rule · Nuclear Regulatory Commission) The U.S. Nuclear Regulatory Commission (NRC) is proposing to amend its regulations to reduce barriers to medical use licensing. This proposed rule responds to Executive Order 14300, “Ordering the Reform of the Nuclear Regulatory Commission,” which requires the NRC to conduct a review and wholesale revision of its regulations. This proposed rule, if adopted, would reduce overly prescriptive regulations, increase flexibility, and modernize radiation safety practices for the medical use of byproduct material. It also would enable more efficient and predictable licensing for emerging medical technologies and reduce unnecessary burden in training and experience requirements for medical authorized users. The NRC is revising guidance for this proposed rule. This proposed rule also would incorporate minor editorial corrections.

Why this matters

Medical-use licensing is a large share of NRC byproduct-material activity, so easing authorized-user training and experience requirements could lower costs for hospitals and clinics and speed adoption of new radiopharmaceuticals and therapies. It also tests how far NRC can deregulate under EO 14300 without weakening radiation safety, a tension shared with the broader materials and radiation-protection modernization efforts.

Source

Link

Briefing card

Reducing Barriers to Medical Use Licensing
Stage: proposed rule · federal-register · 27-jul-2026

The NRC proposes to amend its medical-use licensing regulations to cut overly prescriptive requirements, ease training and experience burdens for authorized users, and make licensing of emerging medical technologies that use byproduct material more efficient and predictable.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: fedreg:2026-15080

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Stages other doctrine resolution introduced proposed rule passed chamber executive action final rule enacted district opinion circuit opinion opinion

build build 392 · ea9c128-dirty · 2026-08-09